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avium subsp. paratuberculosis, the 
etiologic Agent of Johne’s Disease
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Yrjö T. Gröhn3, Michael T. Collins4 and Raúl G. Barletta1*
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Bacterial Diseases, National Animal Disease Center, USDA-ARS, Ames, IA, United States, 3 Population Medicine and 
Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States, 4 Pathobiological  
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Mycobacterium avium subsp. paratuberculosis (MAP) is the etiologic agent of Johne’s 
disease in ruminants causing chronic diarrhea, malnutrition, and muscular wasting. 
Neonates and young animals are infected primarily by the fecal–oral route. MAP attaches 
to, translocates via the intestinal mucosa, and is phagocytosed by macrophages. The 
ensuing host cellular immune response leads to granulomatous enteritis characterized by 
a thick and corrugated intestinal wall. We review various tissue culture systems, ileal loops, 
and mice, goats, and cattle used to study MAP pathogenesis. MAP can be detected in 
clinical samples by microscopy, culturing, PCR, and an enzyme-linked immunosorbent 
assay. There are commercial vaccines that reduce clinical disease and shedding, unfor-
tunately, their efficacies are limited and may not engender long-term protective immunity. 
Moreover, the potential linkage with Crohn’s disease and other human diseases makes 
MAP a concern as a zoonotic pathogen. Potential therapies with anti-mycobacterial 
agents are also discussed. The completion of the MAP K-10 genome sequence has 
greatly improved our understanding of MAP pathogenesis. The analysis of this sequence 
has identified a wide range of gene functions involved in virulence, lipid metabolism, 
transcriptional regulation, and main metabolic pathways. We also review the transposons 
utilized to generate random transposon mutant libraries and the recent advances in the 
post-genomic era. This includes the generation and characterization of allelic exchange 
mutants, transcriptomic analysis, transposon mutant banks analysis, new efforts to gen-
erate comprehensive mutant libraries, and the application of transposon site hybridization 
mutagenesis and transposon sequencing for global analysis of the MAP genome. Further 
analysis of candidate vaccine strains development is also provided with critical discus-
sions on their benefits and shortcomings, and strategies to develop a highly efficacious 
live-attenuated vaccine capable of differentiating infected from vaccinated animals.
Keywords: Mycobacterium avium subsp. paratuberculosis, Johne’s disease, pathogenesis, transposon 
mutagenesis, mutant bank
Abbreviations: MAP, Mycobacterium avium subsp. paratuberculosis; JD, Johne’s disease; MAH, M. avium subsp. hominissuis; 
BMDM, blood-monocyte-derived macrophages; IL, interleukin; INF-γ, interferon-gamma; ELISA, enzyme-linked immuno-
sorbent assay; CD, Crohn’s disease; TraSH, transposon site hybridization mutagenesis; Tn-Seq, transposon sequencing; DIVA, 
differentiate vaccinated from infected animals.
FiGuRe 1 | Mycobacterium avium subsp. paratuberculosis (MAP) properties. 
(A) Acid-fast stain of intestinal epithelium from an experimentally challenged 
bovine reveals MAP (red rods) inside macrophages. (B) Electron microscopy 
clearly shows the rod-shaped mycobacteria magnified over 50,000 times.
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iNTRODuCTiON
Mycobacterium avium subsp. paratuberculosis (MAP) is the 
etiologic agent of Johne’s disease (JD) in ruminants, a chronic 
enteritis with significant economic impact and worldwide dis-
tribution (1). The potential linkage of MAP to Crohn’s disease 
(CD) in humans continues to be intensively investigated with 
dissimilar results (2–4). MAP was first isolated by the German 
scientists Johne and Frothingham in 1895 (5). It causes disease 
primarily in ruminants (cattle, sheep, goats, deer, etc.), but 
there are also reports of infection in non-ruminants, especially 
in wildlife (6). In the United States, annual losses to the cattle 
industry have been estimated from $250 million (7) to $1.5 
billion (8). A recent analysis of published data using a Bayesian 
method (9), adjusting for sensitivity and specificity, determined 
that the true United States dairy herd-level prevalence of MAP 
was actually 91.1% compared to the 70.4% reported in 2007 
(10). In beef cattle, herd-level prevalence of MAP is 7.9% 
(11). Even though JD was first observed in the United States 
in the early 1900s, the focus on research and disease control 
has only increased in the past 20  years. A Voluntary Bovine 
JD Control Program is in place to control JD on farms and 
identify herds with a low risk of infection. Currently, one of 
the most cost-effective and sensitive testing methods for JD is 
the identification of MAP in herds by testing environmental 
fecal samples by culturing from high traffic areas (9). Indeed, 
the use of improved diagnostics coupled with good manage-
ment practices have shown to decrease JD transmission (12). 
Unfortunately, wildlife reservoirs may undermine efforts to 
control JD in domesticated animals until their role in wildlife 
is fully understood (13).
TAXONOMY AND PROPeRTieS
Mycobacterium avium subsp. paratuberculosis is part of the 
Mycobacterium avium complex in the genus Mycobacterium and 
family Mycobacteriaceae. The M. avium complex contains two 
clearly defined species M. avium and M intracellulare. M. avium 
is classified into four subspecies based on the comprehensive 
sequence-based analysis of the 16S-23S ribosomal RNA internal 
transcribed spacer (14, 15): M. avium subsp. avium, M. avium 
subsp. hominissuis (MAH), MAP, and M. avium subsp. silvati­
cum. MAP is a facultative intracellular, Gram-positive, acid-fast 
(Figure 1A) and small (0.5 × 1.5 μm) rod-shaped (Figure 1B) 
bacterium. The cell wall is thick and waxy and made up of 
mycolate and peptidoglycan layers held together by arabinoga-
lactan. It is a slow-growing bacteria with a generation time of 
over 20 h (16). Initial attempts to cultivate MAP in laboratory 
media were unsuccessful (17) and it was hypothesized that the 
inability of MAP to grow under in vitro conditions may be due 
to the lack of some essential growth factor. Later, it was shown 
that MAP was able to grow in media supplemented with extracts 
from other mycobacteria (18, 19) and they concluded that MAP 
lacked the ability to synthesize some essential growth factor that 
is synthesized by other species. Mycobactin, an iron-binding 
siderophore isolated from Mycobacterium phlei, was shown to 
be the growth factor that is essential for the in vitro cultivation 
of MAP (20, 21). Since that time, mycobactin dependency has 
been considered to be taxonomic for MAP. More recently, with 
the genome sequence discussed further below, a molecular 
understanding of mycobactin dependency has been discovered 
by a deletion in the mbtA gene within the mycobactin synthesis 
operon (22, 23).
PATHOGeNeSiS
Johne’s disease causes a chronic diarrhea characterized by a mal-
absorption syndrome that leads to malnutrition and muscular 
wasting (Figure 2A). Neonates and juvenile animals are infected 
mainly via the fecal–oral route. Transmission may also occur 
by the consumption of milk and colostrum from infected cows 
(24). Calves up to 6 months of age are at higher risk of getting 
infected, but the risk of infection drops after this age (25). Mouse 
models have shown that, after ingestion, MAP attachment to 
and translocation through the intestinal mucosa is mediated by 
both M-cells and enterocytes (26). Moreover, studies in tissue 
cultures demonstrated that MAP affects the formation of tight 
junctions in the intestinal mucosa providing a mechanism for 
increased permeability (27). There is significant host–pathogen 
crosstalk during this process as antigens 85 (28), 35 kDa (29), 
MAP oxidoreductase (30), MAP fibronectin-binding protein 
(31, 32), and the histone HupB (33) play important roles in 
MAP epithelial cell adhesion and/or invasion. Previous findings 
using a co-culture of the bovine mammary epithelial cell line 
MAC-T (34) and bovine blood-monocyte-derived macrophages 
(BMDM) suggest that phagosome acidification in MAP-infected 
epithelial cells leads to interleukin (IL)-1β production, mac-
rophage recruitment, and transepithelial migration (35). Bacilli 
are subsequently phagocytosed by these sub- and intra-epithelial 
macrophages (36–38). Once inside phagocytic cells, the ability of 
MAP to survive and replicate within these phagocytic cells plays 
a key role in pathogenesis (39, 40). Moreover, use of a culture 
passage model showed that MAP lipid composition changes in 
macrophages developing a pro-inflammatory phenotype (41).
The ensuing host cellular immune response leads to the typi-
cal granulomatous enteritis pathognomonic of JD (38), charac-
terized by the thick and corrugated appearance of the intestinal 
FiGuRe 2 | Johne’s disease affected animal caused by Mycobacterium avium subsp. paratuberculosis. (A) Severely debilitated cow with common symptoms  
of chronic diarrhea, malabsorption, muscular wasting, and malnutrition. The host cellular immune response leads to the typical granulomatous enteritis seen as 
thickening of the (B) intestinal mucosa with prominent Peyer’s patches, and (C) lymph node showing hyperactive lymphoid tissue (white spots).
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wall (Figure 2B) and inflamed lymph nodes (Figure 2C). Tissue 
macrophages and dendritic cells play a crucial role in the 
recognition of pathogen-associated molecular patterns in the 
innate phase via toll-like receptors (42), as well as in antigen 
processing and the elicitation of cytokine-mediated cellular 
interactions (43). Control of MAP infections are dependent on 
a T helper cell, Th1, type response and the subsequent activa-
tion of macrophages by interferon-gamma (INF-γ) secreted by 
Th1 T  lymphocytes in the acquired immunity phase (44, 45). 
The killing mechanism of these activated phagocytic cells 
involves the generation of nitric oxide by the inducible nitric 
oxide synthase, whose activity has been already demonstrated in 
cattle (46). In this context, the overproduction of nitric oxide is 
particularly high in BMDM isolated from subclinically infected 
animals (47). However, MAP also affects the function of bovine 
macrophages as evidenced by unique mRNA expression profiles 
(48), inhibition of apoptosis and antigen presentation (49), and 
patterns of cytokine expression that have diagnostic significance 
(50). Predominantly, MAP drives T helper cells from infected 
cattle to undergo a Th2 response with enhanced expression of 
IL-4, IL-5, IL-10, and inhibitors of tissue remodeling factors 
(51, 52). This humoral response was confirmed in a neonatal 
calf model (53). Other findings also implicate regulatory T and 
Th17 cells in the immunopathogenesis of JD in both ruminants 
and wildlife (49, 54).
Several models have been developed to study MAP patho-
genesis. However, MAP elicits responses from the ruminant 
host immune system that are not manifested in traditional 
in vitro models. For example, in infected BMDM, MAP bacilli 
multiply over 4–8 days (44, 55), but infection of the murine J774 
macrophage cell line results in a decrease in bacterial loads over 
time (56, 57). Thus, primary phagocytic cells are preferred to 
conduct experiments when studying the interaction of MAP 
with phagocytic cells. A promising systems biology approach 
based on ileal loops has been developed to follow MAP infec-
tion from early to late stages (58). Recently, this model has 
been applied to compare the host transcriptome profile upon 
M. avium subsp. avium and MAP infection. Analysis of cellular 
pathways affected during MAP infection was consistent with 
intestinal mucosal weakening, the activation of a Th2 response, 
and phagocytosis inhibition that was not observed with M. 
avium subsp. avium (59).
DiAGNOSiS AND CONTROL
Infected animals shed MAP in the feces before showing any 
clinical signs, thus acting as a major source of infection to other 
animals in the herd. Early diagnosis of the infection is very 
important to prevent the spread of JD. Various diagnostic tests 
were developed based on the direct and indirect detection of 
MAP (60). The direct detection of MAP in clinical samples can be 
accomplished by (i) microscopy, (ii) MAP isolation by culturing, 
and (iii) the identification of MAP DNA by PCR. Ziehl–Neelsen 
or acid-fast staining has been used for the examination of clinical 
samples (Figure 1A). Acid-fast staining is the simplest, fastest, 
and most economical method of diagnosis, but the specificity 
and sensitivity are low as it is difficult to differentiate between 
MAP and other acid-fast bacilli (61). Ziehl–Neelsen staining 
can be used for the initial screening of MAP, but it has to be 
confirmed by other specific tests, such as PCR and/or immuno-
assays. The isolation of MAP by culturing is the “gold standard” 
for JD diagnosis. The dependence of MAP on mycobactin J 
for growth in specialized laboratory media can also be used 
to discriminate MAP from other acid-fast bacilli. Recently, an 
improved growth medium was described that improves MAP 
recoverability and sensitivity by 1,000-fold (62). Culture-based 
diagnosis is very time consuming as MAP grows extremely slow 
(6–8 weeks for colony formation on solid media). Therefore, a 
very rapid and sensitive PCR-based testing was used for MAP 
detection in clinical and environmental samples (63–65). This 
PCR utilizes primers for a 1.4 kb multicopy insertion element, 
IS900, which is sequence specific to MAP (60, 66). However, the 
presence of IS900-like insertion sequences in other mycobacteria 
was shown to compromise the specificity of this assay leading to 
false-positive results (64, 67). To overcome false-positive results, 
multiplex PCR based on the IS900, IS901, IS1245, and dnaJ gene 
has been developed, but the sensitivity of this test is low due 
to reagent interference and primer dimer formation (60, 68). 
In addition, PCR assays with fecal samples are only 70% sensi-
tive and 85% specific (69). Some good progress has been made 
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identifying and using more specific targets for PCR tests (70–72), 
and this comparative genomic approach has filled a knowledge 
gap in MAP diagnostics. Some of these targets have even been 
used in commercial diagnostic kits.
Diagnostic MAP assays created on the indirect detection are 
based on the host immune response to infection. The delayed-
type hypersensitivity skin test has been developed using a 
Johnin purified protein derivative (73). However, this test is not 
specific as other environmental mycobacteria can also sensitize 
the animal and give false-positive results. So delayed-type 
hypersensitivity skin tests cannot distinguish vaccinated from 
naturally infected animals. As stated previously, MAP infec-
tion leads to a T helper cell response which secrets INF-γ. The 
measurement of this INF-γ level by an enzyme-linked immu-
nosorbent assay (ELISA) can also be used for the diagnosis of 
JD using day-old blood sample culture supernatants stimulated 
with Johnin and co-stimulated with bovine IL-12 and/or human 
IL-2 (74). Unfortunately, MAP purified protein derivatives are 
also used as antigens in the INF-γ assay leading to problems 
with cross-reactivity. The cell wall lipopeptide, L5P, has been 
studied as an alternative MAP antigen for the assay, but the 
INF-γ response has been shown to be lower than with Johnin 
(75). Thus, routinely used methods for MAP diagnosis include 
the detection of antibodies in serum and milk from infected 
animals using a commercial ELISA kit: (i) HerdCheck M. para­
tuberculosis ELISA (IDEXX Laboratories, Inc.), (ii) ParaCheck 
(CSL/Biocor), (iii) SERELISA ParaTB (Synbiotic Corp.), and 
(iv) ID Screen® Paratuberculosis Indirect (IDvet Genetics). 
Compared to PCR diagnosis, an ELISA has a lower sensitivity 
of 50%, but a much greater specificity of 99.8% (76, 77). More 
studies are required to identify MAP specific antigens to develop 
immune-based assays for diagnosis of JD that have a higher level 
of sensitivity.
Control measures to prevent JD include vaccination (the most 
cost-effective), testing, and improved herd management based 
on a producer’s resources, facilities, and operation (78). Unfor-
tunately, though there are JD vaccines that reduce clinical disease 
and shedding, their efficacies are limited and none afford long-
term protective immunity. For example, in the United States, 
Mycopar® (Boehringer Ingelheim Vetmedica, Inc.) is the only 
licensed vaccine against JD in cattle. However, this vaccine was 
derived from M. avium subsp. avium strain 18 (79) and; therefore, 
does not have an optimal antigenic repertoire. Another bacterin, 
Silirum® (Zoetis Animal Health) is being tested in Australia 
and approved for limited use in cattle. This vaccine contains the 
heat-killed MAP 316F strain. This formulation may possess a 
better antigenic repertoire, but while using heat-killed bacteria 
may improve safety, it may also reduce efficacy. Neoparasec® 
(Rhone-Merieux) contains the live-attenuated MAP strain 316F 
while Gudair® (Zoetis Animal Health) is heat-killed 316F and 
both are licensed for use in sheep and goats. However, current 
vaccines cannot distinguish vaccinated from infected animals, 
thus compromising JD diagnostic tests (80), and strain 316F 
was generated in the 1920s by random attenuation procedures 
(e.g., passages on ox bile) that are only now being investigated 
(81). In the final analysis, a vaccine of high efficacy is needed to 
significantly control JD (82).
Testing results on the new generation of human anti-tuberculosis 
vaccines seem to indicate that live-attenuated vaccines provide 
better protection than subunit vaccines (83). As JD is caused by 
a Mycobacterium, it is likely that a similar situation will occur for 
candidate subunit or bacterin-based vaccines. This was actually 
the impetus behind the JD Integrated Program—Animal and 
Plant Health Inspection Service efforts to undertake a stand-
ardized vaccine test program. United States and New Zealand 
researchers contributed 22 blinded live-attenuated vaccine 
candidates to be evaluated in a three-phase study: BMDM, 
mouse, and goat models. Though the methodology for animal 
testing was well developed (84), most of the attenuated trans-
poson mutants tested were first-generation ones and carried the 
Tn5367 transposase which lead to instability. Moreover, there 
were unknowns that could not be ascertained before the start 
of the trial, such as the best immunization route and dosing 
schedule. Nonetheless, important data and reagents were devel-
oped (80). It may still be possible to develop a subunit vaccine 
capable of controlling infections by eliciting the appropriate type 
of humoral immunity (85), especially against antigens expressed 
in the pro-inflammatory phenotype (86).
ZOONOTiC POTeNTiAL
Mycobacterium avium subsp. paratuberculosis is among a list of 
pathogens that have been associated withCD, a human chronic 
inflammatory bowel disease (2, 87, 88). The cross-reactivity of 
MAP antigens with those in humans, such as the zinc transporter 
8 protein, may underlie the etiology of these diseases (89). MAP is 
also postulated to be involved in the progression of HIV infection 
and other immune dysfunction diseases: multiple sclerosis, sar-
coidosis, type 1 and 2 diabetes mellitus, Hashimoto’s thyroiditis, 
and Parkinson’s disease (90–96). Over the years, several studies 
have investigated the role of MAP in CD with conflicting results 
(4, 97–100). MAP has been isolated from CD patients by cultur-
ing blood, breast milk, and tissue biopsy samples, and samples 
were shown positive for IS900 by PCR (101–103). Also by this 
method, MAP was present in the gut of 92% of CD patients and 
26% of control individuals (98). Humans are exposed to MAP 
from various sources that could be contaminated from infected 
animals, such as drinking water with feces, milk, etc. (104). In 
the United Kingdom, a study revealed that even after pasteuriza-
tion, MAP was detected by IS900 PCR in 7% of retail milk for 
human consumption (105). Nonetheless, this is highly dependent 
on the pasteurization method since the application of a stand-
ard high-temperature short-time pasteurization results in the 
destruction of MAP (106). However, some bacteria survived the 
sub-pasteurization heat treatment at lower temperatures used for 
cheese manufacture. Thus, though humans are widely exposed 
to MAP, susceptible individuals with a compromised immune 
system, due to other illness or genetic factors, may be at higher 
risk for infection and disease. In these individuals, MAP may 
survive and multiply inside gut macrophages leading to immune 
dysregulation and inflammation of the intestinal wall resulting 
in a “leaky gut” (http://www.crohnsmapvaccine.com). Microbes 
and food materials penetrate the leaky gut causing massive wall 
inflammation leading to chronic inflammatory bowel disease.
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Currently a combination of anti-inflammatory, anti-
mycobacterial, and immunosuppressant drugs are used or in 
trials for CD treatment. Initially, only anti-tuberculosis drugs 
were used for treatment of MAP infections in humans, but the 
results were not promising. Later macrolides (e.g., azithromycin 
and erythromycin), rifabutin, and clofazimine have been used 
with limited success, but the treatment regimen is very lengthy 
(2, 66, 107–109). A comprehensive study evaluated culture 
methods for the determination of MAP in vitro drug suscepti-
bility and concluded that the BACTEC™ MGIT™ system was 
more rapid and reliable (110). In addition, in vitro studies using 
drug combinations of anti-microbials and immunomodulators 
displayed synergistic effects that could be applied to CD treat-
ment (111). Therefore, more studies are needed to identify novel 
drugs and/or targets for the development of better therapeutics 
against MAP to shorten and simplify the treatment. Regarding 
MAP pathogenesis, the European Food Safety Authority has 
conducted a thorough study and indicated that MAP is eligible 
to be listed for Union intervention based on Article 5(3) of the 
Animal Health Law (112). Several species of mammals and birds 
were listed as susceptible species, including Bovidae, Cervidae, 
and Leporidae, but there was no consensus on the zoonotic risk 
of MAP in the context of human diseases, such as CD.
GeNOMiCS
The MAP bovine strain K-10 genome has been sequenced, anno-
tated, and re-examined by optical mapping (22, 113, 114). The 
updated K-10 genome is 4,829,781 bp encoding 4,350 protein-
encoding ORFs with a 69.3% GC content. In the genome, about 
60% of the ORFs have similar sequences in microbial genetic 
databases, but only approximately 35% have well predicted or 
identified functions (115). Nonetheless, about 75% of the MAP 
genes have counterparts in Mycobacterium tuberculosis with 
39 predicted proteins that are unique to MAP. This genome 
possesses a high redundancy rate due to gene duplications, 
particularly for those involved in lipid metabolism and redox 
processes. Gene functions include 150 transcriptional regula-
tors, 16 polyketide synthesis, 14 two-component regulatory 
systems, 16 serine–threonine protein kinases, 8 mammalian cell 
entry (mce), 20 insertion elements, and 5 putative prophages. 
Sequencing also iden tified and mapped genes involved in 
glycolysis, pentose phosphate pathway, tricarboxylic acid cycle, 
and glyoxylate cycle (116). Important differences between the 
genomes of K-10 and M. tuberculosis human strain H37Rv 
include the following: (i) no intact Pro-Glu-polymorphic 
GC-rich sequences (PE-PGRS) genes, (ii) 47 fewer Pro-Pro-Glu 
(PPE) genes in M. tuberculosis (117), and (iii) the presence of a 
truncated salicyl-AMP ligase gene (mtbA) which may explain 
the MAP mycobactin biosynthesis defect discussed earlier (22).
Other MAP strains with complete sequences include the 
human strain MAP4 (118) and another bovine strain JII-1961 
(119). Partial MAP genomic sequences include 10-4404, 
2015WD-1, 2015WD-2, ATCC19698, JQ5, S5, S397, JIII-386, and 
several human isolates (118, 120–122). The MAP ovine genomes 
of strains S397 and JIII-386 differ by one inversion to the MAH 
human strain 104, while two inversions are detected between 
K-10 and MAH, with additional differences involving duplica-
tions, deletions, and polymorphisms. Based on these analyses, 
ovine isolates seem to be an intermediate in the evolution of 
MAP bovine strains from MAH human strains (115), although 
this is not definitely established (121). However, the more closely 
related bovine and human isolates (118, 120) may be the latest 
strains that diverged in evolution acquiring specific host adapta-
tions in their genomes.
TRANSPOSON MuTAGeNeSiS
The identification and functional analysis of genes involved in 
the pathogenesis of MAP requires molecular genetic tools to 
manipulate its genome. Because the MAP cell wall is very thick 
and impermeable, it is difficult to introduce plasmid vectors. The 
shuttle plasmid vector pMV262 carrying a mycobacterial origin 
of replication (oriM) and an Escherichia coli origin of replication 
(oriE) have been used to transform MAP (123). However, the 
transformation efficiency was very low; therefore, a phage-
mediated transduction process was developed to introduce 
DNA into MAP (124). Shuttle phasmids (phagemids) carry-
ing the mycobacteriophage TM4 (125) and an E. coli cosmid 
have been widely used for the genetic manipulation of MAP. 
More recently, the generation of MAP mutant libraries using 
transposon mutagenesis has been the major approach to define 
virulence determinants and identify genes that are essential 
and non-essential (126). Two types of transposons have been 
extensively used in mycobacteria to generate random mutant 
banks: (i) IS1096-derived and (ii) Himar1-derived transposons 
(Figure 3).
Tn5367 (GenBank Accession KM232614) was the first trans-
poson widely used in mycobacteria including MAP (126–128). 
This transposon (3,381 bp) carries a kanamycin-resistant drug 
marker (aph), and the IS1096 transposase (tnpA) and resolvase 
(tnpR). This transposon has the transposase within the trans-
posed element (126) resulting in a relatively high transposition 
frequency (ca. 1.0 × 10−5), at least in Mycobacterium smegmatis 
(129). Tn5367 transposes by a cutting and paste mechanism 
(130) and may insert in another gene creating either a wild-
type or mutated gene, depending on precise or imprecise exci-
sions, in the location of the original insertion. The transposon 
can be delivered into Mycobacterium by the thermosensitive 
phasmid derivative of mycobacteriophage TM4 (126). Since the 
IS1096 transposase is located within the transposed element, 
the corresponding MAP mutants may not be stable enough to 
conduct long-term in vivo experiments where bacilli multiply 
to large numbers. An improved IS1096-derived transposon, 
Tn5370 (GenBank Accession KM232615), was constructed 
by removing ORFs dispensable for transposition (e.g., tnpR), 
therefore, reducing the size to 2,295  bp (128, 130). More-
over, the transposase was engineered into the phasmid outside of 
the transposable element. Thus, Tn5370, as opposed to Tn5367, 
generates stable mutants upon transposition. This transposon 
has the advantage of possessing a hygromycin (hyg) marker 
within the transposable element outflanked by the γ-δ resolvase. 
This construction allows for the excision of the drug marker 
and the generation of unmarked transposon insertion mutants. 
FiGuRe 3 | Structure of mycobacterial transposons utilized to generate random mutant libraries. Inverted repeat (IR) for Tn5367 or Tn5370 (filled triangle),  
or Himar1-derived transposon (striped triangle); tnpR, IS1096 resolvase; aph, kanamycin-resistant gene; tnpA, IS1096 transposase; res, resolution site for 
transposon gamma-delta; hyg, hygromycin resistant gene; and C9 Himar1, Himar1 transposase.
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However, neither Tn5367 nor Tn5370 transposes randomly in 
mycobacteria (127, 130).
Himar1-derived transposons have also been used to generate 
random mutant libraries in M. tuberculosis and MAP (131–134). 
The Himar1 transposon (MycoMarT7) was engineered into the 
same TM4 phasmid derivative described above. This vector car-
ries the highly active C9 Himar1 transposase outside the inverted 
repeats, thus yielding stable mutants. In addition, this vector car-
ries the aph drug marker and a T7 promoter that reads outward 
to facilitate identification of insertion sites by in vitro transcrip-
tion and cDNA synthesis (131). The major advantage of the 
Himar1 derivative is the almost fully random recognition sequence 
(5′-TA-3′) versus the recognition sequence of IS1096-derived 
transposons (5′-NNPy(A/T)A(A/T)NN-3′) showed experimen-
tally to have a transposition bias in both M. tuberculosis and 
MAP (127, 130). Most of the MAP transposon mutant libraries 
were made with Tn5367 (127, 128, 135, 136) and fewer libraries 
have been constructed using the Himar1-derived transposon 
MycoMarT7 (132, 133). Our group has constructed a Himar1 
library for MAP and used it to demonstrate random genomic 
insertions (134).
MOLeCuLAR GeNeTiCS iN THe  
POST-GeNOMiCS eRA: CANDiDATe 
vACCiNe APPLiCATiONS
Our understanding of MAP pathogenesis has greatly improved 
based on the completion of the MAP K-10 genome sequence, and 
the availability of advanced molecular biology and bioinformatics 
tools. MAP genomics has many applications, such as molecular 
detection, determining the molecular evolution of MAP as a 
pathogen, and identifying virulence determinants, drug targets, 
attenuation targets for vaccine development, and/or diagnostic 
antigens. Several strategies were used to mine the MAP genome 
for virulence determinants or important diagnostic antigens 
(137–139). One approach relied on identifying MAP genes with 
known M. tuberculosis homologs known to play important roles 
in pathogenesis (140, 141). Many of these studies described below 
have generated deletion mutants to identify the role of these 
genes in pathogenesis. Usually, phasmids are used to deliver the 
allelic exchange substrate into MAP to produce the desired gene 
deletion by homologous recombination. For example, based 
on the attenuation of M. tuberculosis leuD mutants (140), the 
corresponding MAP leuD mutants were constructed by allelic 
exchange, characterized by carbon and nitrogen source utiliza-
tion, and showed to be attenuated in mice (142, 143). Likewise, a 
mutant of MAP lipN was constructed and displayed lower levels 
of colonization in mice compared to the wild-type strain (144). 
Similarly, lsr2, pknG, and relA deletion mutants were generated 
(145) and later in vivo mice studies revealed that relA mutants 
were immunogenic, but had decreased pathogenicity (146). 
Other studies constructed sigH and sigL deletion mutants, infect-
ing bovine macrophages and mice to demonstrate that this gene 
plays a role in pathogenesis (147, 148). Recently, sigH and lipN 
deletion mutants were validated as promising live-attenuated 
vaccine candidates in goats (149). Nonetheless, these meritorious 
studies are not comprehensive since genetic islands were identi-
fied in the MAP genome demonstrating a gene organization 
different from the closely related MAH (150). Indeed, differences 
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in gene organization may lead to a context-dependent function 
(e.g., even homologous genes in MAP and MAH may play dif-
ferent roles in pathogenesis). This effect is further compounded 
by findings indicating host genome adaptations (115).
In the context of vectored subunit vaccines, success has been 
achieved in the expression of MAP antigens in Lactobacillus 
salivarius using a codon optimization strategy (151, 152). 
Multi-antigen virally vectored vaccines were also engineered 
and tested in mice and cattle. In this context, the vaccine des-
ignated HAV is a fusion of two secreted and two cell surface 
MAP proteins whose DNA coding sequence was inserted into 
the human adenovirus 5 and Modified Vaccinia Ankara delivery 
vectors. Vaccination of naive C57BL/6 mice resulted in a highly 
immunogenic response with significant levels of IFN-γ and a 
humoral response against the recombinant antigens (153). The 
vaccine provided moderate protection against challenge. This 
vaccine was also tested in cattle with promising results being 
well tolerated, showing no cross-reactivity against bovine 
tuberculin, providing some protection against challenge in a 
calf model and eliciting CD4+, CD8+ IFN-γ producing T-cell 
populations and, upon challenge, developed early specific Th17 
T-cells (154). In addition, a non-recombinant Lacotbacillus casei 
used as a probiotic immunomodulated and reduced pathology 
in a mouse MAP infection model (155). Moderate success has 
been attained with recombinant MAP Hsp70 proteins resulting 
in a reduction of bacterial shedding upon experimental infec-
tion without compromising the diagnosis of bovine tuberculosis 
(156, 157) and showed some promise as a therapeutic vaccine in 
cattle (158). Lipoarabinomannan-enriched glycolipid extracts 
used as potential subunit vaccines against MAP yielded a 
pro-apoptotic response in bovine macrophages and reduced 
shedding (159, 160). Studies have also been conducted with 
purified antigens or antigen cocktails. For example, superoxide 
dismutase and antigen 85B were shown to elicit T-cell responses 
consistent with protection in mice (161, 162). These results were 
further advanced using DNA vector vaccines (145). Various 
MAP protein cocktails were also tested in mice and cattle, 
showing reduced tissue burden (163), and INF-γ and humoral 
responses, respectively (164). Nonetheless, the extensive experi-
ence of researchers in the human tuberculosis vaccine field has 
led to the consensus that live-attenuated vaccines are the best 
approach for vaccination against mycobacterial diseases (83).
Gene expression in MAP is complex and global regulation has 
been associated with 19 putative sigma factors with 12 belonging 
to common mycobacterial gene families. Specific sigma factors 
may be involved in the expression of survival and virulence genes 
(165). In addition, MAP virulence determinants are regulated by 
the LuxR–LuxI quorum sensing system (166). Transcriptomic 
analysis has been applied extensively and these studies generated 
large expression databases under conditions of environmental 
stress (144), iron limitation (167), intracellular survival within 
BMDM, tissue localization in vivo (168), and ligated jejuno-ileal 
loops (58, 59). Some differentially regulated genes such as atpC, 
clpB, dnaJ, dnaK, groEL2, infB, kdpE, mbtC, and pmmA corre-
spond to essential genes in M. tuberculosis (131, 144, 169). Other 
genes identified as non-essential more likely to be involved in 
pathogenesis rather than general physiological functions: aceAB, 
clpX, relA, htpX, lipL, lipN, and lpqP. Indeed M. tuberculosis 
homologs of lipL, lipN, aceAB, and lpqP were also identified as 
being required for intracellular survival within macrophages by 
a genetic approach (170). Another insight from transcriptomic 
studies revealed significant differences in gene expression 
with MAP metabolic genes being shut down in tissues, while 
phagocytic cells upregulated genes involved in iron acquisition 
and intracellular survival (168). Interestingly, the analysis of 
databases from different studies does not reveal any significant 
correlations. Moreover, the fold-changes in gene expression 
levels differed widely from one study to another. Nonetheless, 
except for specific and restricted conditions, a common feature 
is that approximately 20–25% of the genes in the MAP genome 
change their expression levels based on the condition. Likewise 
for M. tuberculosis, little correlation was observed among genes 
that were up- or downregulated in macrophages or infected mice, 
and those identified by a genetic approach as being required for 
survival in macrophages and mice (170, 171). In retrospect, 
these results are not surprising as genetic methods establish 
gene requirements for a certain condition as an outcome of a 
cumulative selection process during the infection, independent 
of their mode of regulation. In this context, transcriptomic 
approaches may miss a significant number of constitutively or 
transiently expressed genes involved in pathogenesis. As tran-
scriptomic approaches require discrete rather than continuous 
samplings, most appropriate time points could be missed.
Transposon mutagenesis is another strategy that has been 
used to identify MAP virulence genes. In this approach, genes 
are disrupted using random transposition to generate a mutant 
library where each mutant is marked with a transposon. Mutants 
are then screened under different in  vitro and in  vivo condi-
tions for the functional analysis of genes. Mutants that have a 
mutation in genes that are essential will not survive. A library 
of 5,060 Tn5367 transposon mutants was generated to apply a 
transposon–chromosome junction site sequencing protocol 
in order to identify the disrupted genes (127). They analyzed 
1,150 mutants and identified 970 unique insertion sites. Based 
on sequencing analysis, they selected 11 mutants for mouse 
infection experiments and identified some potential virulence 
genes (gcpE, pstA, kdpC, papA2, impA, umaA1, and fabG2_2). 
In our study, we generated and screened a MAP transposon 
library of 13,536 mutants, identifying genes potentially involved 
in pathogenesis (e.g., MAP1152, MAP1156, MAP1566, and lsr2) 
(128). Another study used the Himar1 transposon in MAP to 
isolate 111 mutants attenuated in BMDM from a random screen 
of 2,290 (132). Unfortunately, all of these studies have limita-
tions: (i) the screening and analysis methods used are laborious 
and time consuming, especially for slow-growing MAP and 
(ii) the library used for screening is partial because of transposon 
bias (134) so it is not possible to perform the functional analysis 
of the entire MAP genome. To overcome these limitations, it is 
necessary to generate a comprehensive MAP mutant library and 
design new and more robust approaches to perform global gene 
functional analysis.
Transposon site hybridization (TraSH) has been applied for 
the global analysis of the M. tuberculosis genome (131). In this 
method, a high-density transposon mutant library is generated 
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and the mutants are pooled. DNA microarray is then applied 
to map all transposon insertion sites. This approach has some 
limitations, such as poor resolution, limited dynamic range, 
and the requirement to develop DNA microarrays. Recently, a 
new method has been established based on next-generation 
deep sequencing to analyze the essentiality of genes on a whole-
genome basis called transposon sequencing (Tn-Seq) (172). 
Tn-Seq involves the generation of a comprehensive mutant 
library using a transposon that inserts randomly without any 
biases. The mutants are pooled to isolate genomic DNA so 
the transposon chromosomal junctions can be amplified and 
sequenced using an Illumina or another suitable platform. This 
approach has been applied for M. tuberculosis to define essential 
genes under various conditions (173, 174). More recently, the 
Tn-Seq method was used to classify MAP essential genes by 
generating a pool of approximately 100,000 Himar1 transposon 
mutants (133). However, we have demonstrated that Himar1 
transposons recombine with significant loci-dependent biases, 
making these collections highly underrepresented (134). The 
application of the Tn-Seq system to a highly saturated Himar1 
transposon mutant library will overcome these limitations and 
provide a global approach to the identification of MAP essential 
genes and virulence determinants.
PeRSPeCTive AND OveRALL SuMMARY
Sequencing the MAP K-10 genome, and the availability of 
advanced molecular biology and bioinformatics tools have 
allowed the screening and characterization of transposon 
mutants to identify specific genetic loci involved in pathogenesis, 
suggesting novel strategies for the control and diagnosis of JD. 
In addition, several candidate genes for strain attenuation have 
been mutagenized by allelic exchange and the corresponding 
mutants were tested with promising results in mice, goats, and 
cattle. We consider that vaccination with a live-attenuated vaccine 
is the most cost-effective control measure for MAP infection in 
livestock. The embodiment of such a vaccine would require the 
construction of a strain with two deletion mutations and with 
the capability to differentiate vaccinated from infected animals.
In summary, this article opens with a brief review of JD 
epidemiology and the staggering economic losses followed by 
MAP taxonomy and cultivation. The main mechanisms of patho-
genesis related to the invasion of the intestinal epithelium and 
the underlying humoral and cellular responses are discussed. 
Infection models are concisely summarized thereafter. The article 
then shifts to the multiple methods of JD diagnosis, including 
acid-fast stain, culture, PCR, and the use of ELISA to detect the 
antibody and INF-γ responses. The control of JD is explained 
in the context of commercially available vaccines and their 
efficacies. This section also includes results of a recent multi-
institutional live-attenuated JD vaccine testing program. MAP 
zoonotic potential is described based on the diagnostic methods 
used to detect MAP in human samples along with the various 
treatment options. Subsequently, we focus on genomics, includ-
ing the analysis of bovine and ovine genome sequence isolates. 
This leads to the transposon mutagenesis section where we define 
the transposons and vectors used and summarize the results 
obtained with mutant banks. The final post-genomic section 
discusses the construction of new attenuated mutants by deletion 
mutagenesis and their vaccine potential. We also discuss antigen 
and antigen cocktails that have been suggested for subunit vac-
cine formulations. The manuscript concludes with the discussion 
of gene expression, global regulators, methods of wide genomic 
analysis, such as TraSH mutagenesis and Tn-Seq analysis, and our 
perspective on current and future vaccine efforts.
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